Document Detail

The risks associated with aprotinin use: a retrospective study of cardiac cases in Nova Scotia.
MedLine Citation:
PMID:  23132043     Owner:  NLM     Status:  Publisher    
PURPOSE: In light of the concerns about the safety of aprotinin, we wanted to determine if aprotinin use during cardiac surgery was associated with an increased risk of mortality and morbidity compared with the use of tranexamic acid (TXA). We hypothesized that use of aprotinin is associated with a higher risk of adverse outcomes than use of TXA in our patient population. METHODS: In this retrospective study at a single surgical centre, we examined primary in-hospital outcomes of postoperative mortality, new acute renal failure, and perioperative blood transfusion, and we also investigated secondary outcomes of stroke, infection, and prolonged stay in the intensive care unit (ICU). The effect of the type of antifibrinolytic on outcome was evaluated for aprotinin cases matched 1:1 with TXA cases using propensity score. RESULTS: This study included 3,340 patients who received antifibrinolytics during cardiac surgery (376 patients received aprotinin and 2,964 patients received TXA). Patients who received aprotinin were more often elderly and female; they were more commonly presented with congestive heart failure, atrial fibrillation, renal failure, and lower hemoglobin, and they underwent complex and/or urgent surgery. In the matched sample, in-hospital mortality was significantly higher in the aprotinin group (10.9%) compared with the TXA group (5.9%), and ICU stay >72 hr was significantly increased in the aprotinin group (30.0%) compared with the TXA group (21.7%). There was no significant difference in blood product administration between the two groups. CONCLUSIONS: Aprotinin was associated with an increased risk of in-hospital mortality and morbidity following cardiac surgery, and aprotinin was not associated with a decrease in blood product requirements. Continued use of aprotinin in cardiac surgery should follow careful consideration, weighing the demonstrated risks and potential advantages compared with other TXA.
Robert E G Riddell; Karen J Buth; John A Sullivan
Related Documents :
23616673 - Evaluation of an electrolyte repletion protocol for cardiac surgery intensive care pati...
17551783 - Role of hyperbaric oxygen therapy in the treatment of postoperative organ/space sternal...
17993283 - Relationships between biochemical markers of bone and cartilage degradation with radiol...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-7
Journal Detail:
Title:  Canadian journal of anaesthesia = Journal canadien d'anesthesie     Volume:  -     ISSN:  1496-8975     ISO Abbreviation:  Can J Anaesth     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-7     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8701709     Medline TA:  Can J Anaesth     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Division of Cardiac Surgery, Dalhousie University, Halifax, NS, Canada,
Vernacular Title:
Les risques associés à l'utilisation d'aprotinine: une étude rétrospective des cas de chirurgie cardiaque en Nouvelle-Écosse.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Palladium, iridium and ruthenium complexes with acyclic imino-N-heterocyclic carbenes and their appl...
Next Document:  Relative potency of pregabalin, gabapentin, and morphine in a mouse model of visceral pain.